Loading…
Teva Pharmaceutical Industries Limited is projected to rise to $40.64 by 2027, a +23% move from its current price of $32.95. TEVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $32.33 | $32.96 | $33.59 | +0.02% |
| Jul 14 | $32.08 | $32.96 | $33.86 | +0.03% |
| Jul 15 | $31.90 | $32.97 | $34.07 | +0.05% |
| Jul 16 | $31.74 | $32.97 | $34.25 | +0.07% |
| Jul 17 | $31.60 | $32.98 | $34.41 | +0.08% |
| Jul 18 | $31.48 | $32.98 | $34.56 | +0.10% |
| Jul 19 | $31.37 | $32.99 | $34.70 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.37 | $32.99 | $34.70 | +0.12% |
| Week 2 | $30.75 | $33.03 | $35.47 | +0.24% |
| Week 3 | $30.30 | $33.07 | $36.09 | +0.35% |
| Week 4 | $29.93 | $33.11 | $36.62 | +0.47% |
| Week 5 | $29.61 | $33.14 | $37.10 | +0.59% |
| Week 6 | $29.33 | $33.18 | $37.55 | +0.71% |
| Week 7 | $29.07 | $33.22 | $37.97 | +0.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Teva Pharmaceutical Industries Limited (TEVA) is a healthcare company with a current price of $34.22 and a market capitalization of $39.85B. It is ranked 372 by market cap within the provided dataset. The near-term price outlook for 2026 shows a neutral stance, with an average price of $34.22 and a range from $28.35 to $45.74, indicating a wide but balanced potential path in the year ahead.
A major floor 14.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 7.2% above — a clean break opens room to run.
A major ceiling 12.6% above — clearing it would confirm fresh momentum.
Key TEVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TEVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.85 | Sell | $33.47 | Sell |
| MA 10 | $33.77 | Sell | $33.62 | Sell |
| MA 20 | $33.54 | Sell | $33.67 | Sell |
| MA 50 | $34.26 | Sell | $33.52 | Sell |
| MA 100 | $32.73 | Buy | $32.55 | Buy |
| MA 200 | $29.78 | Buy | $29.77 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.59 | Neutral |
| Stoch RSI (14) | 21.21 | Neutral |
| CCI (20) | -53.66 | Neutral |
| Williams %R (14) | -75.73 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -0.78 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 24.27 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 45.76 | Neutral |
| Momentum (10) | -0.67 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 33.22 | Sell |
| ADX (14) | 9.47 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is mixed but leaning constructive, with a bullish sentiment overall. RSI(14) is 50, while the 50-day moving average stands at $33.76 and the 200-day moving average at $28.97. The 30-day price range runs from $29.90 to $39.16, with a key support at $31.48 and resistance at $36.25.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.35 | $32.95 | $42.62 | 0% | Neutral | |
| $33.26 | $40.64 | $51.94 | +23% | Bullish | |
| $39.48 | $49.17 | $64.55 | +49% | Bullish | |
| $44.20 | $55.89 | $74.97 | +70% | Bullish | |
| $47.87 | $61.37 | $83.81 | +86% | Bullish | |
| $52.17 | $67.70 | $93.93 | +105% | Bullish | |
| $53.29 | $69.96 | $98.46 | +112% | Bullish | |
| $56.74 | $75.27 | $107.32 | +128% | Bullish | |
| $63.62 | $85.26 | $123.02 | +159% | Bullish | |
| $72.64 | $98.28 | $143.41 | +198% | Bullish | |
| $94.60 | $133.57 | $204.34 | +305% | Bullish | |
| $199.21 | $302.00 | $495.52 | +817% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.35 | $32.95 | $38.68 | +0.00% |
| August 2026 | $27.77 | $32.52 | $38.92 | -1.30% |
| September 2026 | $28.44 | $33.46 | $40.35 | +2.88% |
| October 2026 | $28.85 | $34.08 | $41.38 | +1.87% |
| November 2026 | $28.62 | $33.94 | $41.43 | -0.43% |
| December 2026 | $29.20 | $34.73 | $42.62 | +2.33% |
Click any year to see its month-by-month TEVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TEVA to range from $28.35 to $42.62 through 2026. The $32.95 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The TEVA price prediction for 2027 points to an average of $40.64 (low $33.26, high $51.94) — a potential gain of +23% on today's $32.95. Momentum favours further upside here.
In 2028, TEVA is projected to trade between $39.48 and $64.55, averaging $49.17 — a potential gain of +49% from today's $32.95. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Teva Pharmaceutical Industries Limited's 2029 outlook centres on $55.89, within a $44.20 to $74.97 range. That is up +14% on the projected 2028 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2030, TEVA could reach as high as $83.81, with a base case around $61.37 and support toward $47.87 — roughly +86% from $32.95. Buyers look set to stay in control over this stretch.
Expect TEVA to range from $52.17 to $93.93 through 2031. The $67.70 average target implies a +105% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The TEVA price prediction for 2032 points to an average of $69.96 (low $53.29, high $98.46) — a potential gain of +112% on today's $32.95. Buyers look set to stay in control over this stretch.
In 2033, TEVA is projected to trade between $56.74 and $107.32, averaging $75.27 — a potential gain of +128% from today's $32.95. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Teva Pharmaceutical Industries Limited's 2034 outlook centres on $85.26, within a $63.62 to $123.02 range. That is up +13% on the projected 2033 average. That marks a +159% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, TEVA could reach as high as $143.41, with a base case around $98.28 and support toward $72.64 — roughly +198% from $32.95. Momentum favours further upside here.
Expect TEVA to range from $94.60 to $204.34 through 2040. The $133.57 average target implies a +305% move from current prices. That is up +36% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The TEVA price prediction for 2050 points to an average of $302.00 (low $199.21, high $495.52) — a potential gain of +817% on today's $32.95. Momentum favours further upside here.
Investing $1,000 in TEVA today (≈ 30.349014 TEVA) could be worth
$9,165.39
+$8,165.39 (+817%) by 2050 · US Dollar
Based on the average projected TEVA price of $302 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TEVAwould be worth at today's price.
$1,000 invested in TEVA on Jul 10, 2025 (≈ 60.496065 TEVA) would be worth
$1,993.35
+$993.35 (+99.3%) today · 1.99× · US Dollar
Based on a TEVA entry price of $16.53 vs. today's $32.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.64 | $951.21 | -4.9% |
| 1 month ago | $33.58 | $981.24 | -1.9% |
| 3 months ago | $30.82 | $1,069.11 | +6.9% |
| 6 months ago | $32.79 | $1,004.88 | +0.5% |
| 1 year ago | $16.53 | $1,993.35 | +99.3% |
| All time (5.0y) ago | $9.11 | $3,616.9 | +261.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TEVA forecast.
Our base-case forecast reaches $66.00 around 2031.
Implied market cap at $66.00: $76.85B
The multi-year forecast shows a bullish trajectory beyond the near term. For 2030, the model projects an average price of $65.09 with a min of $50.32 and a max of $89.93, and a 90.2 in the ROI metric. By 2040, the average rises to $144.08 with a min of $100.30 and a max of $224.38, delivering a 321 in ROI.
In 2050, the average is $335.31 with a min of $215.98 and a max of $562.09, and a projected ROI of 879.9. Across these years, sentiment remains BULLISH, reflecting sustained upside potential while acknowledging the inherent uncertainty of any forecast.
Tap a question to reveal the answer.
2030 min: $50.32, avg: $65.09, max: $89.93 with ROI 90.2 and sentiment BULLISH.
The forecast shows a neutral stance in 2026, then bullish momentum with rising averages and positive ROI into 2027–2050, culminating in substantial upside (e.g., ROI 25.3 in 2027, 879.9 in 2050). These are estimates, not guarantees.
Yes. The max price in 2031 is $100.62, indicating a path that can exceed $100 under the forecast assumptions.
Current price is $34.22 and market cap is $39.85B.
RSI(14) is 50; SMA(50) is $33.76; SMA(200) is $28.97. The 30-day range is $29.90 to $39.16, with support at $31.48 and resistance at $36.25; annualized volatility is 40%.
Teva Pharmaceutical Industries Limited Community Discussion
0Share your Teva Pharmaceutical Industries Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.